乌鸦传媒

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.

In 2014, ASCO published a on systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC). In March 2022, the FDA approved ¹⁷⁷Lutetium-PSMA-617 (¹⁷⁷Lu-PSMA-617), a radioligand therapy that delivers targeted beta-particle radiation to prostate-specific membrane antigen (PSMA)-expressing cancer cells. The approval was based on the randomized controlled trial (RCT) reported by , which showed a significant improvement in radiographic progression-free survival and overall survival (OS) in patients with PSMA-positive mCRPC. The availability of this theranostic option provided a strong signal to update the 2014 guideline with a rapid recommendation for ¹⁷⁷Lu-PSMA-617. Complete updates to the mCRPC guidelines are underway.

A targeted electronic literature search was conducted to identify any additional RCTs of radioligand therapy in this patient population. An updated guideline Expert Panel was formed to review the evidence and to review and approve the recommendation.

Read an interview with one of the guideline panel members here.